Erschienen in:
11.01.2021 | Original Research
Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis (ASQA): A Multicenter Post-marketing Surveillance Study
verfasst von:
Farhad Gharibdoost, Amir-Hossein Salari, Mansour Salesi, Faegheh Ebrahimi Chaharom, Peyman Mottaghi, Mansour Hosseini, Maryam Sahebari, Mohammadali Nazarinia, Zahra Mirfeizi, Mohammadreza Shakibi, Hamidreza Moussavi, Mansour Karimifar, Karim Mowla, Hadi Karimzadeh, Nassim Anjidani, Ahmadreza Jamshidi
Erschienen in:
Advances in Therapy
|
Ausgabe 2/2021
Einloggen, um Zugang zu erhalten
Abstract
Introduction
Phase IV post-marketing surveillance studies are needed to evaluate the real-world safety and effectiveness of drug products. This study aimed to evaluate the safety and effectiveness of biosimilar etanercept (Altebrel, AryoGen Co., Iran) in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA).
Methods
In this open-label, multicenter, prospective, observational, post-marketing surveillance study, 583 patients received biosimilar etanercept 25 mg twice weekly or 50 mg once weekly and were followed up to 12 months. The primary objective was to evaluate the safety of biosimilar etanercept by documenting all the adverse events in the case report forms throughout the study period. The secondary objective was to evaluate the effectiveness of biosimilar etanercept in study patients, where longitudinal changes in health assessment questionnaire (HAQ), pain, and disease activity scores were assessed.
Results
A total of 583 patients (44.80 ± 13.09 years of age) were included and followed for an average of 8.12 ± 3.96 months. Among all patients, 172 (29.50%) experienced at least one adverse event, and injection site reaction, abdominal pain, and upper respiratory tract infection were the most common. HAQ scores decreased from 1.32 ± 0.77 at baseline to 0.81 ± 0.61 at 12 months in patients with RA/PsA (p < 0.01) and from 0.82 ± 0.58 at baseline to 0.66 ± 0.63 at 12 months in patients with AS (p = 0.18). Pain scores decreased from 6.49 ± 2.41 at baseline to 3.51 ± 2.39 at 12 months (p < 0.01).
Conclusion
The results demonstrated the real-world safety and effectiveness of biosimilar etanercept in patients with RA, PsA, and AS.
Trial Registration
ClinicalTrials.gov identifier NCT04582084.